Výsledky vyhledávání - "Thomas J R, Beveridge"

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors

Autor: Beloo Mirakhur, Thomas J. R. Beveridge, Arturo Loaiza-Bonilla, Antonio Tito Fojo, Clarisse Dromain

Publikováno v: The Oncologist

Introduction Tumor quantity while receiving cancer therapy is the sum of simultaneous regression of treatment‐sensitive and growth of treatment‐resistant fractions at constant rates. Exponential rate constants for tumor regression/decay (d) and g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238ed1e0dcc4c50b1c4af6308348a276
http://europepmc.org/articles/PMC8018300

Zobrazit plný text záznamu

Residual deficits in functional brain activity after chronic cocaine self-administration in rhesus monkeys

Autor: Linda J, Porrino, Hilary R, Smith, Thomas J R, Beveridge, Mack D, Miller, Susan H, Nader, Michael A, Nader

Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Previous studies in humans and in animals have shown dramatic effects of cocaine on measures of brain function that persist into abstinence. The purpose of this study was to examine the neurobiological consequences of abstinence from cocaine, using a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f728bbab07b9dc0f9997aad2dc579a66
https://pubmed.ncbi.nlm.nih.gov/34385608

Zobrazit plný text záznamu

Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

Autor: Katharine Thomas, Robert A. Ramirez, Saurabh P Nagar, James A. Kaye, David Ray, Thorvardur R. Halfdanarson, Heloisa P. Soares, Rohan Parikh, Muhammad Wasif Saif, Beloo Mirakhur, Samantha Kurosky, Thomas J. R. Beveridge

Publikováno v: Journal of gastrointestinal oncology. 10(4)

Background: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progressionfree survival (PFS) in patients with unresectabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8547fd71eddd6c3c86c52c98bba043a9
https://pubmed.ncbi.nlm.nih.gov/31392048

Zobrazit plný text záznamu

The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Autor: Saurabh P Nagar, Katharine Thomas, Heloisa P. Soares, David Ray, Wasif M. Saif, Rohan Parikh, Catherine A Lubeck, James A. Kaye, Thomas J. R. Beveridge, Beloo Mirakhur, Samantha Kurosky

Publikováno v: Journal of Clinical Oncology. 36:e16174-e16174

e16174Background: Somatostatin analogs (SSA), such as OCT and LAN, are used to treat GEP-NETs. LAN is effective for carcinoid syndrome (CS) control in both SSA-experienced and -naive patients (pts)...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8a1d2b2960b6cdc401d4d606179fd1f
https://doi.org/10.1200/jco.2018.36.15_suppl.e16174

Zobrazit plný text záznamu

Tumor growth and regression rate constants from the CLARINET study as surrogate endpoints for progression free survival: A novel assessment approach in cancer therapy

Autor: Beloo Mirakhur, Thomas J. R. Beveridge, Antonio Tito Fojo, Julia Wilkerson, Arturo Loaiza-Bonilla, Clarisse Dromain

Publikováno v: Journal of Clinical Oncology. 36:e24329-e24329

e24329Background: Tumor size following cancer-related therapy is the result of regression of the treatment-sensitive fraction and growth of the treatment-resistant fraction, occurring simultaneousl...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb7106caccb9e204a84f04acf36d2639
https://doi.org/10.1200/jco.2018.36.15_suppl.e24329

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání